Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
HTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1–associated myelopathy
Allison K. Maher, Aris Aristodemou, Nicolas Giang, Yuetsu Tanaka, Charles R.M. Bangham, Graham P. Taylor, Margarita Dominguez-Villar
Allison K. Maher, Aris Aristodemou, Nicolas Giang, Yuetsu Tanaka, Charles R.M. Bangham, Graham P. Taylor, Margarita Dominguez-Villar
View: Text | PDF
Research Article Immunology

HTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1–associated myelopathy

  • Text
  • PDF
Abstract

Human T cell leukemia virus type 1 (HTLV-1) is a retrovirus with preferential CD4+ T cell tropism that causes a range of conditions spanning from asymptomatic infection to adult T cell leukemia and HTLV-1–associated myelopathy (HAM), an inflammatory disease of the CNS. The mechanisms by which HTLV-1 induces HAM are poorly understood. By directly examining the ex vivo phenotype and function of T cells from asymptomatic carriers and patients with HAM, we show that patients with HAM have a higher frequency of CD4+CD8+ double-positive (DP) T cells, which are infected with HTLV-1 at higher rates than CD4+ T cells. Displaying both helper and cytotoxic phenotypes, these DP T cells are highly proinflammatory and contain high frequencies of HTLV-1–specific cells. Mechanistically, we demonstrate that DP T cells arise by direct HTLV-1 infection of CD4+ and CD8+ T cells. High levels of CD49d and CXCR3 expression suggest that DP T cells possess the ability to migrate to the CNS, and when cocultured with astrocytes, DP T cells induce proinflammatory astrocytes that express high levels of CXCL10, IFN-γ, and IL-6. These results demonstrate the potential of DP T cells to directly contribute to CNS pathology.

Authors

Allison K. Maher, Aris Aristodemou, Nicolas Giang, Yuetsu Tanaka, Charles R.M. Bangham, Graham P. Taylor, Margarita Dominguez-Villar

×

Figure 5

Phenotype of DP T cells in uninfected controls, asymptomatic carriers, and patients with HAM.

Options: View larger image (or click on image) Download as PowerPoint
Phenotype of DP T cells in uninfected controls, asymptomatic carriers, a...
(A) t-SNE plot from a concatenated sample of DP T cells (n = 11 each group). (B) t-SNE plots depicting the cell clusters identified by Phenograph. (C) Pie charts showing the fraction of cells within each cell cluster in uninfected controls or HTLV-1–infected groups. (D) Bar graph showing the distribution (fraction) of cells from each patient group in each identified cluster. (E) Heatmap of the expression of markers by each cluster displayed as modified Z scores using median values. (F) Box-and-whisker plots showing the expression of extracellular markers ex vivo in DP T cells from different patient groups (n = 16 UC, n = 20 AC lPVL, n = 20 AC hPVL, n = 13 HAM). Wilcoxon signed-rank unpaired test for comparisons between UC and AC lPVL, AC lPVL and AC hPVL, and AC hPVL and HAM (F). **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts